trichostatin a

Trichostatin A (TSA) is an organic compound originally isolated as an antifungal antibiotic from Streptomyces species. It is a potent and selective inhibitor of histone deacetylases (HDACs), specifically targeting class I and II HDAC enzymes at low nanomolar concentrations while not affecting class III HDACs (sirtuins). By inhibiting HDAC activity, TSA prevents the removal of acetyl groups from lysine residues on histone tails, leading to increased histone acetylation and altered chromatin structure. This results in changes in gene expression by making DNA more accessible to transcription factors. TSA has demonstrated broad-spectrum epigenetic activities including induction of cell cycle arrest at G1/G2 phases, promotion of apoptosis through upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes, inhibition of angiogenesis in tumor models, and induction of differentiation in various cell types. It has shown antitumor activity in preclinical cancer models as well as potential neuroprotective effects in animal studies. Trichostatin A is used primarily as a research tool; it is not approved for clinical use but has been investigated for hematological malignancies (Phase I/II trials) and onychomycosis (Phase I trial)[3][5][8].

Other names

trichostatin aTSA antibiotic2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide